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Abstract
Purpose Primary care studies suggest that thrombocytosis (platelet counts > 400 × 109/L) is associated with an increased risk of
colorectal cancer (CRC). We aimed to establish whether this marker has significant stratification value in patients seen in
secondary care.
Methods A retrospective review of 2991 patients referred to our colorectal 2-week-wait (2WW) pathway between August 2014
and August 2017. Patient demographics were recorded prospectively, and local electronic records systems were used to retrieve
full blood counts (FBC) and cancer diagnoses. Patients with no recent platelet count at the time of referral or incomplete records
were excluded.
Results 2236 patients were included in this evaluation. There was no significant difference in the age distribution of those with
thrombocytosis and those without. There were significantly more females in the thrombocytosis group (72.1% vs 53.9%, chi-
squared 24.63, p < 0.0001). 130 CRCs were detected (5.8%) and patients with thrombocytosis were more likely to have CRC
(OR 2.62, 95% CI 1.60–4.30). The CRC diagnosis rate was significantly higher in females with thrombocytosis (10.3% vs 2.9%,
chi-squared 19.41, p < 0.0001) and males with thrombocytosis (16.1% vs 7.9%, chi-squared 4.62, p = 0.032).
Conclusion Thrombocytosis appears to have stratification value in the 2WW population. Further evaluation of its value alone or
in combination with other stratification tests is required.
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Introduction
Colorectal cancer (CRC) is common with around 42,000 new
diagnoses made annually in the UK [1]. Outcomes in the UK
lag behind the rest of Europe despite nearly two decades of 2-
week-wait (2WW) pathways and other targets introduced to
address this issue [2]. The desire for diagnosis at an earlier
stage led to the introduction of broader referral criteria for
CRC in 2015 with the aim of investigating all those with a
risk of CRC ≥ 3%. However, these criteria for urgent referral
to secondary care are largely based on patient age and symp-
toms [3]—the latter are often associated with later-stage dis-
ease and are inherently non-specific. The search for objective
markers that may help to stratify risk remains attractive in this
context.
We introduced straight to test (STT) colonoscopy in 2014
as part of our 2WW pathway [4]. A full blood count (FBC)
was specified for inclusion with every referral. We have pre-
viously demonstrated the value of anaemia in those patients
referred on an urgent pathway although compliance with sub-
mission of FBC results has been poor [5, 6]. An FBC also
provides a platelet count and thrombocytosis (platelet count
> 400 × 109/L) appears to have value for risk stratification of
colorectal cancer in primary care [7]. We aimed to evaluate its
utility in the secondary care setting by undertaking a review of
existing data for patients referred on a 2WW colorectal cancer
pathway at our institution. We report on its value as a single
marker of risk, as well as its association with other recognised
parameters such as age, sex and anaemia.
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Adult patients referred to the Colorectal Service at
Nottingham University Hospitals under the 2WW pathway
for CRC are prospectively recorded on a local database in
accordance with best practice guidance for audit of straight
to test pathways. The name, date of birth, age, sex, hospital
ID, NHS number, date of referral and indication for referral is
recorded for each patient.
Data for haemoglobin (Hb) and platelet counts at the time
of referral were collected from the hospital electronic
reporting system retrospectively. Cancer diagnoses, CRC
and other cancer (OC) outcomes were collected from hospital
electronic reporting system.
Cohort
All patients referred under the 2WW pathway between 01
August 2014 and 31 August 2017 for suspected CRC were
identified from the referral database populated by specialist
nurses at the Colorectal Service at Nottingham University
Hospitals NHS Trust. Duplicate and rejected referrals were
identified and excluded. Patients with no full blood count
(FBC) on referral, no investigations or unknown outcome
were excluded from subsequent analysis of outcomes.
Exposure and covariates
Anaemia was diagnosed according to the World Health
Organization (WHO) definitions of a haemoglobin of <
120 g/L in women or < 130 g/L in men, based on the most
recent Hb at the time of referral. Thrombocytosis was defined
as platelets > 400 × 109/L in line with primary care studies [7].
The presence or absence of anaemia and thrombocytosis was
evaluated for all patients.
Outcome definition
Colorectal cancer diagnosis was determined from investiga-
tion outcomes. Evidence of lower GI malignancy on colonos-
copy, CT scans and histology reports reviewed at our cancer
multi-disciplinary team (MDT) meeting that confirmed ade-
nocarcinomas were reviewed for diagnosis. Non-colorectal
cancer diagnoses were also recorded.
Statistical analysis
Data were assessed for normality using histograms and a
Shapiro-Wilk test. Comparisons were made between continu-
ous variables using the Student t test if normally distributed or
Mann-Whitney if not normally distributed. Categorical data
was summarised using frequencies and percentages. Missing
data were classified in a separate category and included in
models. Comparisons were made between categorical data
using chi-squared tests. Logistic regression analysis was used
to test the association between diagnosis of colorectal cancer
and thrombocytosis accounting for age, gender and anaemia.
Univariate analysis was undertaken with age as a continuous
variable; a multivariate model was then built including all
factors associatedwith colorectal cancer in the univariate anal-
ysis. All statistics were performed using Stata Version 16
(Stata Corp, College Station, TX, USA). Tests of significance
were considered significant if a p value of less than 0.05 was
obtained.
Results
A total of 2991 patients referred for 2WWinvestigation during
the study period were available for review; 2236 (74.8%) were
included in the analysis. 755 patients (25.2%) were excluded
from the study. In total 394 (13.2%), had no FBC available,
225 (7.5%) were not investigated due to clinical judgement/
patient choice, 82 (2.7%) had missing clinic/blood test infor-
mation, 45 (1.5%) did not attend their appointment and 9
(0.3%) were excluded due to database error/duplication.
Demographic characteristics are shown in Table 1. There
was no significant difference in the age distribution of those
with thrombocytosis and those without. 55.5% of the cohort
were females; there were significantly more females in the
thrombocytosis group than the group with normal platelets
(72.1% vs 53.9%, chi-squared 24.63, p < 0.0001).
A total of 130 CRCs (5.8%) and 52 other cancers (2.3%)
were diagnosed in this cohort. CRC diagnosis was more likely
in patients with thrombocytosis (12.4% vs 5.2%, chi-squared
17.70, p = < 0.0001) compared with those with a normal plate-
let count, significant for both females (11% vs 2.8%, chi-
squared 23.70, p = < 0.0001) and males (16.1% vs 7.9%,
chi-squared 4.62, p = 0.032). Thrombocytosis was significant-
ly associated with advanced (stage 3/4) CRC diagnosis
(19.1% vs 8.5%, chi-squared 14.4, p < 0.0001) and with a
diagnosis of right-sided cancers (34% vs 9.6%, chi-squared
11.87, p = 0.001) vs left-sided and rectal cancers. Patients with
anaemia were also significantly more likely to be diagnosed
with CRC (9.5% vs 3.5%, chi-squared 35.33, p < 0.0001)
compared with those with a normal haemoglobin.
Univariate analysis identified sex, age, anaemia and
thrombocytosis as significant risk factors for CRC diagnosis
as summarised in Table 1. Multivariate logistic regression of
the whole dataset confirmed the association of thrombocytosis
with CRC diagnosis after adjustment for gender, age and anae-
mia (OR 2.62, 95% CI 1.60–4.30). Repeat analysis was com-
pleted with non-CRCs excluded, yielding the same results
(OR 2.58, 95% CI 1.57–4.25). No association was found in
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a comparative analysis on thrombocytosis for the diagnosis of
non-CRCs (OR 0.76, 95% CI 0.26–2.18).
Discussion
We demonstrate that thrombocytosis has value in stratifying
risk for this cohort of patients after referral on a 2WW pathway
for CRC. Our study period mostly pre-dates the Bailey et al.
paper [8] highlighting the value of platelets in primary care risk
stratification, and it is unlikely that this publication would have
affected our results. We note that thrombocytosis appears more
significant in our female population—the reverse of the primary
care study in which males showed a greater increase in risk.
However, symptoms such as change in bowel habit are more
common in females than males, leading to more of this group
being referred on a 2WWpathway despite a lower risk of CRC.
This population is therefore selected from the general popula-
tion on the basis of symptoms, which may also explain the lack
of increased risk for other malignancies. As the risk of CRC
increases with age, it is understandable that the CRC group
selected from a 2WW cohort is comparatively older. In our
dataset, there was no significant association between age and
thrombocytosis. Overall, we demonstrate that thrombocytosis
confers an increased CRC risk in the referred population inde-
pendent of gender, age and anaemia.
An FBC is a cheap easily accessible test that appears to
provide two objective markers of risk in haemoglobin and
platelet count [5, 8]. However, despite our referral form
requesting submission of this data since 2014, only 82.8%
of referrals complied with this. As a retrospective study of
thrombocytosis, there was little choice but to exclude those
without a recorded FBC (394), which is a limitation of our
study. Local discussions with primary care commissioners
identified a concern that waiting for test results to make a
referral may cause delays in suspected cancer cases. The
2WW initiative in the UK requires that a GP suspecting a
diagnosis of cancer sends a referral to the secondary care pro-
vider within 24 h, without pre-requisite tests stipulated [9].
Following integration of the Faecal Immunochemical Test
(FIT) into our urgent pathway in 2019, an FBC is now man-
datory at the time of referral. Incomplete referrals are returned
for completion.
Within this cohort, 5.8% of patients were diagnosed with
CRC, satisfying the 3% NICE threshold for urgent investiga-
tion. However, the 2.9% detection rate in women without
thrombocytosis suggests some subsets of this cohort may fall
below that cut-off. The presence of thrombocytosis in 19.2%
of CRC diagnoses reaffirms the notion that a single parameter
is insufficient for risk stratification.
Association between thrombocytosis and right-sided can-
cers is of great interest, given the increased likelihood of false-
negative FIT results from right-sided cancers [10]. In our co-
hort, thrombocytosis was also significantly associated with
later-stage CRC, though not specifically metastatic cancer. In
some cases within this dataset, thrombocytosis was the only
abnormal stratification parameter in early-stage CRC.
Identifying cohorts at increased risk of CRC is key to im-
proving diagnosis at earlier stages when outcomes are
favourable [2]. Increasing demand for 2WW diagnostic ca-
pacity requires more individualised risk stratification in order
to improve rates of early diagnosis and clinical effectiveness
of such pathways [11]. We have combined anaemia with fae-
cal immunochemical testing (FIT) in our local pathway [12],
and whilst FIT is useful at the extremes of faecal Hb (f-Hb)
concentrations, there is a broad range (locally between 4 and
100) that would benefit from additional discriminatory value.
Scoring systems such as FAST hold promise in this regard
[13]. Here, we postulate that adding values from an FBC such
as Hb and platelet count may improve the performance char-
acteristics of such a score. It might be argued that such param-
eters could be extrapolated to support individualised decision-
making in screening programmes to further decrease CRC
mortality and minimise iatrogenic harm [14]. The English
Bowel Cancer Screening Programme could recommend an
FBC to identify anaemia or thrombocytosis meriting further
investigation for patients with faecal haemoglobin concentra-
tions below the 120-μg Hb/g faeces cut-off threshold.
Table 1 The proportion of patients diagnosed with CRC; univariate and
multivariate analysis for thrombocytosis accounting for age, gender and
anaemia. Patients with thrombocytosis were more likely to have CRC
(OR 2.62, 95% CI 1.60–4.30, p = < 0.001) but not non-colorectal cancers
(analysis not shown—OR 0.76, 95% CI 0.26–2.18)
Parameter Total CRC Univariate analysis Multivariate analysis
Total patients 2236 130 OR (95% CI) p value OR (95% CI) p value
Age (SEM) 68.19 (0.27) 74.22 (0.87) 1.05 (1.03–1.07) < 0.001 1.04 (1.02–1.06) < 0.001
Male (%):female (%) 994 (44.5%):1242 (55.5%) 83 (63.8%):47 (36.2%) 2.32 (1.60–3.35) < 0.001 2.44 (1.67–3.58) < 0.001
Anaemia (%) 860 (38.5%) 82 (63.1%) 2.74 (1.92–3.93) < 0.001 1.83 (1.23–2.73) 0.003
Thrombocytosis (%) 201 (9.0%) 25 (19.2%) 2.51 (1.58–3.98) < 0.001 2.62 (1.60–4.30) < 0.001
SEM standard error of mean
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